Time-to-Progression of NSCLC from Early to Advanced Stages: An Analysis of data from SEER Registry and a Single Institute

The average time required for cancers to progress through stages can be reflected in the average age of the patients diagnosed at each stage of disease. To estimate the time it takes for non-small-cell lung cancer (NSCLC) to progress through different tumor, node and metastasis (TNM) stages and size...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2016-06, Vol.6 (1), p.28477-28477, Article 28477
Main Authors: Yuan, Ping, Cao, Jin Lin, Rustam, Azmat, Zhang, Chong, Yuan, Xiao Shuai, Bao, Fei Chao, Lv, Wang, Hu, Jian
Format: Article
Language:English
Subjects:
692/4028/67/1612/1350
692/699/67/1612/1350
Adult
African Americans
Aged
Aged, 80 and over
Asian people
Black or African American
Carcinoma, Non-Small-Cell Lung - pathology
Disease Progression
Epidemiology
Ethnicity
Female
Humanities and Social Sciences
Humans
Lung cancer
Lung Neoplasms - pathology
Male
Males
Medical screening
Middle Aged
multidisciplinary
Neoplasm Staging - methods
Patients
Registries
Regression analysis
Science
Science (multidisciplinary)
SEER Program
Surveillance
Tumors
White People
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The average time required for cancers to progress through stages can be reflected in the average age of the patients diagnosed at each stage of disease. To estimate the time it takes for non-small-cell lung cancer (NSCLC) to progress through different tumor, node and metastasis (TNM) stages and sizes, we compared the mean adjusted age of 45904 NSCLC patients with different stages and tumor sizes from Surveillance, Epidemiology and End Results (SEER) cancer registry database and our institute. Multiple-linear-regression models for age were generated adjusting for various factors. Caucasian, African-American and Asian patients with stage IA cancers were on average 0.8, 1.0 and 1.38 adjusted years younger, respectively, than those with stage IIIB cancers (p 
ISSN:2045-2322
2045-2322
DOI:10.1038/srep28477